Last reviewed · How we verify
Isoprenaline Only Product
Isoprenaline Only Product, developed by the University of Southern Denmark, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a unique mechanism that may offer a competitive edge. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Isoprenaline Only Product |
|---|---|
| Also known as | isoproterenol |
| Sponsor | University of Southern Denmark |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Treatment of PAF With the Synaptic System (NA)
- Epinephrine Versus Isoprenaline During Out-of-Hospital Cardiac Arrest With Asystole (PHASE4)
- Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome (PHASE4)
- Wide Area Circumferential Ablation With Contact Force Versus Cryoballoon Ablation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isoprenaline Only Product CI brief — competitive landscape report
- Isoprenaline Only Product updates RSS · CI watch RSS
- University of Southern Denmark portfolio CI